WHO ICTRP trial
RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in…
CTIS2024-510926-19-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-510926-19-00 |
|---|---|
| Public title | RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis |
| Primary sponsor | Universitair Medisch Centrum Groningen |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Netherlands |
| Conditions | Myelofibrosis;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Registration date | Aug 23, 2025 |
| Target size | 14 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: